ArticleFrontiers in oncology2019

An Engineered Fusion Protein Anti-CD19(Fab)-LDM Effectively Inhibits ADR-Resistant B Cell Lymphoma.

Dongmei Fan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.